Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft certificate-of-analysis minimum data standard — submissions

The 13 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-003/2
Series
Public comment period
Version
1.0
Published
12 Dec 2023
Last reviewed
12 Dec 2023
Next review
12 Dec 2024
Identifier
10.71829/cei.cp.3
Certainty
Not rated
Cycle
2023 Q4
Window
11 Oct 2023 – 08 Nov 2023
Status
Closed
Submissions
13

§2Submissions and responses

13 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Vasilisa Immelmann, PharmD, PhD Health-technology assessment agency · submitting on regulatory science
DRAFT-COA-MINIMUM-/001 received 14 Oct 2023

Nothing prevents a chromatogram being reprocessed until it passes

This is a submission on the draft of CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations, made by a respondent who assesses supplier documentation professionally.

Integration parameters can be adjusted after acquisition, and nothing in the draft requires the sequence of processing to be recorded. A result presented as a single determination may be the last of several.

The respondent proposes that the standard require an audit trail of processing, retained with the primary data.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted in part11 Dec 2023

The secretariat accepts the principle and adopts a narrower requirement.

The standard now requires the processing method and its version to be recorded with every result and the primary data to be retained. A full audit trail is recommended and not required, since it depends on software many laboratories in scope do not run.

Professor Bartolomeu Nkosi-Lindegaard, PhD Professor of Regulatory Science · submitting on regulatory science
DRAFT-COA-MINIMUM-/002 received 14 Oct 2023

A conformance claim is not defined and will be made loosely

The respondent has read CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations in draft and makes a single submission.

The respondent states that the draft nowhere defines what it means for a determination to conform, and that in the absence of a definition the phrase will be applied to determinations that meet some of the requirements.

The respondent proposes an explicit definition and a requirement that partial conformance be described as such.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted09 Dec 2023

The secretariat accepts this submission. An undefined conformance claim is a marketing phrase.

Conformance is now defined as meeting every requirement classified as critical together with the stated system suitability criteria, partial conformance must be described by naming the requirements not met, and a claim of conformance made without the sampling statement is not conformant.

Dr Wolfram Quintanilha, PhD (Pharmacology) Regulatory affairs, marketing-authorisation holder · submitting on regulatory science · industry submission
DRAFT-COA-MINIMUM-/003 received 15 Oct 2023

The additional determinations required would materially increase release testing cost

This submission concerns CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations and makes one point.

The submission is made on behalf of a manufacturer. It states that the draft adds two determinations to those in existing compendial practice, and estimates the additional analytical burden per batch.

The submission does not dispute the analytical reasoning and asks that one of the two be made conditional rather than universal.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted in part14 Nov 2023

The secretariat accepts this submission in part. One determination is made conditional on a stated risk factor. The other is retained because the evidence supplied by the respondent does not bear on whether it is necessary, only on what it costs.

One of the two determinations is now required only where the stated risk factor is present, with the factor defined in the scope, and the other is retained as a universal requirement with the reasoning stated. The submission is identified as an industry submission.

Dr Yusuf Whitmarsh-Obi, MD, MSc (Clinical Trials) University department of public health · submitting on evidence synthesis
DRAFT-COA-MINIMUM-/004 received 17 Oct 2023

Absence of evidence is presented in a form a reader will take as negative evidence

The respondent submits on the draft of CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations. A documentation standard is the one standard whose failure a purchaser can detect without a laboratory, which makes it the most consequential of the series.

Where the Institute has identified no study, the draft states that no evidence was found. In several places that sentence sits immediately after a paragraph describing an adverse outcome, and the juxtaposition invites the reading that the compound was studied and found wanting.

The respondent proposes a standing formulation, used identically wherever the situation arises, distinguishing an outcome that was studied and not demonstrated from an outcome that has not been studied at all.

This submission should be read alongside submission 002, which arises on the same draft.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted22 Nov 2023

The secretariat accepts this submission. The two states are different, they support different decisions, and the draft rendered them in language a reader could not reliably separate.

A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at a glance.

Dr Quentin Zimmerthal, PhD (Chemistry), CChem Independent analytical consultancy · submitting on analytical chemistry
DRAFT-COA-MINIMUM-/005 received 17 Oct 2023

The draft prescribes a procedure where it should state performance

The respondent submits on CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations, on a matter that is not specific to this draft but is visible in it.

Several clauses specify a gradient, a column chemistry and a temperature. The respondent states that fixing these prevents a laboratory from using a validated equivalent, and that the Institute settled on stating performance when it scoped the series.

The respondent proposes that the prescriptive clauses be converted into performance requirements with the prescribed conditions retained as a worked example.

The respondent has read submission 001 and puts a further matter to the secretariat.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseAccepted25 Nov 2023

The secretariat accepts this submission. The draft departed from the position settled when the series was scoped, and the departure was not deliberate.

The prescriptive clauses are converted to performance requirements, the specific conditions are retained as a worked example clearly labelled as one, and a laboratory using a different validated procedure that meets the stated performance reports a conformant determination.

Dr Liesbeth Nyquist-Obiora, PhD (Pharmaceutics) Regional hospital pharmacy department · submitting on pharmaceutics
DRAFT-COA-MINIMUM-/006 received 20 Oct 2023

The standard should state a pass limit

The respondent’s comment on the draft of CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations arises from handling certificates of this kind in practice.

The respondent states that a standard which reports a figure without a limit leaves the reader without a criterion, and that suppliers will set their own.

The respondent proposes a universal acceptance limit for the determination.

The respondent has read submission 003 and asks that this submission be considered with it.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseNot accepted12 Dec 2023

The secretariat does not accept this submission. An appropriate limit depends on the compound, the presentation and the intended route, none of which the standard fixes.

The standard states performance and reports the figure as determined. Setting a universal limit would attach a pass or fail to materials whose acceptable ranges genuinely differ, which would be a stronger claim than the Institute can support. The submission remains published in full and the point is recorded in the limitations.

Dr Anselm Thorsby-Nakamura, PhD (Chemistry), CChem Independent analytical consultancy · submitting on analytical chemistry
DRAFT-COA-MINIMUM-/007 received 22 Oct 2023

Quantitative claims are reproduced without the method that produced them

The respondent notes that CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations will be used as a checklist by people who have not read the rest of the series, and submits with that in view.

Several figures in the draft are quoted from sources that determined them by different methods. A figure obtained by one determination and a figure obtained by another are not comparable, and the draft places them in the same sentence without distinguishing them.

The respondent, an analytical chemist, proposes that every quantitative claim carry the method that produced it at the point of use rather than in the reference.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseAccepted12 Dec 2023

The secretariat accepts this submission. Placing two figures side by side is an implicit claim that they are the same kind of quantity, and in the cases identified they were not.

Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.

Dr Fitzwilliam Danquah-Öberg, PhD (Chemistry), CChem Independent analytical consultant · submitting on analytical chemistry
DRAFT-COA-MINIMUM-/008 received 22 Oct 2023

The scope does not say which materials the standard excludes

The respondent read the draft of CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations and has confined this submission to a single requirement.

The scope states what the standard applies to. The respondent states that in practice the difficult question is whether a borderline material is in scope, and that the draft leaves it to be inferred.

The respondent proposes an explicit exclusion list.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted29 Nov 2023

The secretariat accepts this submission. A scope stated only positively is a scope that will be stretched.

The scope now states both what the standard applies to and what it does not, with the excluded classes named and, where another standard covers them, cross-referenced.

Eamon Sandringham-Adu, MSc (Clinical Pharmacy) Regional hospital pharmacy department · submitting on medicines information
DRAFT-COA-MINIMUM-/009 received 25 Oct 2023

A determination does not record the version of the standard it was made under

Having read the draft of CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations, the respondent puts one point to the secretariat.

The respondent states that the standard will be revised and that results reported under different versions will circulate together, indistinguishable from one another.

The respondent proposes that the standard identifier and version be carried on the face of every determination.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted27 Nov 2023

The secretariat accepts this submission. A conformance claim against an unspecified version is not a conformance claim.

Every determination reported under this standard now carries the standard identifier and version on its face, and a claim of conformance that does not identify the version is recorded by the Institute as not conformant.

Rukayat Zaleski-Mbeki, MSc, FIBMS University department of clinical biochemistry · submitting on clinical biochemistry
DRAFT-COA-MINIMUM-/010 received 25 Oct 2023

Nothing requires a laboratory to demonstrate ongoing performance

Having read the draft under consultation, which concerns CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations, the respondent submits as follows.

The respondent states that suitability criteria assessed within a run demonstrate that the run worked and not that the laboratory performs consistently over time.

The respondent proposes participation in a proficiency scheme as a condition of conformance.

Submission 002 raises an adjacent matter. The respondent regards the two as separable and addresses only this one.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted in part25 Nov 2023

The secretariat accepts this submission in part. A trend requirement on system suitability data is added. Proficiency scheme participation is not made a condition of conformance, for the same reason competence requirements are not.

The standard now requires that system suitability results be trended across runs and that a determination report whether the trend was within the laboratory's stated limits, which places the demonstration inside the document the Institute can read.

Dr Melisande Thorsby-Nakamura, PhD (Chemistry), CChem Independent analytical consultancy · submitting on analytical chemistry
DRAFT-COA-MINIMUM-/011 received 02 Nov 2023

Nothing in the standard addresses transfer of the method between laboratories

The respondent read CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations in draft. The point applies to it and to the series generally.

The respondent states that determinations under this standard will be performed by different laboratories on the same material and that without transfer criteria their results are not comparable.

The respondent proposes a transfer protocol with acceptance criteria for inter-laboratory agreement.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted in part02 Dec 2023

The secretariat accepts this submission in part. Acceptance criteria for agreement between laboratories are added. A full transfer protocol is not, because transfer is a quality-system activity rather than a determination and the series does not address quality systems.

The standard now states the maximum difference between laboratories analysing the same sample at which results are treated as agreeing, and requires that a comparison across laboratories state whether that criterion was met.

Dr Theodora Ingelbrecht, MD, PhD University teaching hospital, department of endocrinology · submitting on clinical pharmacology
DRAFT-COA-MINIMUM-/012 received 03 Nov 2023

The document should state what a reader ought to do

The respondent has read CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations in draft and makes one submission.

The draft assesses evidence and stops. The respondent, a practising clinician, states that a reader arriving at the document with a decision to make is left to convert an assessment into an action without help, and proposes that each document close with a recommendation.

The respondent argues that other evidence bodies issue recommendations and that declining to do so transfers the difficult part of the work to the reader.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseNot accepted09 Dec 2023

The secretariat does not accept this submission, and records that the point is a reasonable one rather than a misunderstanding.

The Institute assesses evidence and does not issue recommendations, because a recommendation embeds values and a resource context that the Institute does not hold and cannot state. That constitutional limit is published on the methodology page and is not varied by consultation. The submission remains published in full.

Dr Fenella Steenkamp-Ferreira, BPharm, PhD Regional hospital pharmacy department · submitting on pharmacy practice
DRAFT-COA-MINIMUM-/013 received 06 Nov 2023

A field classified as critical is not one a reading turns on

This submission addresses the draft of CEI-MS-14, Certificate-of-analysis minimum data standard for synthetic peptide preparations from the standpoint of a reader who will rely on a conformance claim against it.

The respondent examines the fields classified as critical and states that two of them are administrative rather than interpretive, so that a certificate could be rendered uninterpretable by an omission that changes no reading.

The respondent proposes that a field be classified critical only where its absence changes what the figure means.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted in part28 Nov 2023

The secretariat accepts this submission in part. One field is reclassified as recommended on the test the respondent proposes. The second is retained as critical because its absence prevents the determination being attributed to a batch.

The classification test is now stated in the standard: a field is critical where its absence changes the meaning of a reported figure or prevents attribution to a batch. One field has been reclassified under that test and the reasoning recorded.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.